Profile data is unavailable for this security.
Mergers & acquisitions
Acquired company | LLY:NYQ since announced | Transaction value |
---|---|---|
Mablink Bioscience SAS | 37.84% | -- |
POINT Biopharma Global Inc | 57.91% | 1.38bn |
Versanis Bio Inc | 95.53% | 1.93bn |
Emergence Therapeutics AG | 85.30% | 8.33m |
Sigilon Therapeutics Inc | 85.30% | 316.64m |
Data delayed at least 15 minutes, as of Jun 07 2024 21:10 BST.